Investor Relations

Advanced therapies for the sports medicine and severe burn care markets

Day High:
Day Low:
Volume:
on
Data Provided by Refinitiv. Minimum 15 minutes delayed.

Investor Relations

Press Releases

October 24, 2024

Vericel to Report Third-Quarter 2024 Financial Results on November 7, 2024

August 29, 2024

Vericel to Present at the Morgan Stanley Global Healthcare Conference on Friday, September 6, 2024

August 26, 2024

Vericel Announces FDA Approval and Commercial Availability of MACI Arthro

Events and Presentations

Stock Quote & Analyst Coverage

Stock Quote ()

Change
Volume
Today's Open
Previous Close
Today's High
Today's Low
52 Week High
52 Week Low
Vericel Corporation is covered by the following analysts.
Ryan Zimmerman
BTIG
Caitlin Cronin
Canaccord Genuity
Swayampakula Ramakanth
H.C. Wainwright & Co.
Jeff Cohen
Ladenburg Thalmann
Mike Kratky
Leerink
George Sellers
Stephens
Joshua Jennings, MD
TD Cowen
Richard Newitter
Truist

Vericel Corporation is followed by the analysts listed. Please note that any opinions, estimates or forecasts regarding Vericel Corporation's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Vericel Corporation or its management. Vericel Corporation does not by its reference or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.